Danaher Corporation (NYSE:DHR) reported first-quarter results that exceeded earnings estimates but fell short on revenue.
The company recorded adjusted earnings per share of $2.06, surpassing the analyst consensus of $1.94 by $0.12. Revenue totaled $5.95 billion, below the expected $5.99 billion, though it increased 3.5% compared to the prior-year quarter.
The revenue shortfall was attributed to a weaker-than-usual respiratory season impacting its Cepheid business, which offset strong performance in Bioprocessing and better-than-anticipated results in Life Sciences.
For the second quarter, Danaher projected core revenue growth in the low-single-digit percentage range. The company maintained its full-year core revenue growth outlook of 3% to 6% and raised its adjusted EPS guidance to a range of $8.35 to $8.55, up from its prior forecast of $8.35 to $8.50. The midpoint of $8.45 was above the analyst consensus estimate of $8.40.
